Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207805 | 1.00 | PTPRC (0.39) | PTPRCL3MBTL1HDAC1HDAC2GAA | |
| SCHEMBL10208030 | 1.00 | PTPRC (0.39) | PTPRCL3MBTL1HDAC1HDAC2GAA | |
| SCHEMBL10207606 | 1.00 | PTPRC (0.39) | PTPRCL3MBTL1HDAC1HDAC2GAA | |
| SCHEMBL320670 | 1.00 | PTPRC (0.39) | PTPRCL3MBTL1HDAC1HDAC2GAA | |
| SCHEMBL320216 | 0.86 | PTPRC (0.38) | PTPRCL3MBTL1F10 | |
| SCHEMBL14916630 | 0.86 | PTPRC (0.38) | PTPRCL3MBTL1F10 | |
| SCHEMBL10207799 | 0.86 | PTPRC (0.38) | PTPRCL3MBTL1F10 | |
| SCHEMBL10207810 | 0.81 | CTSK (0.42) | ITGB3ITGA2BMAPT | |
| SCHEMBL10206922 | 0.81 | CTSK (0.42) | ITGB3ITGA2BMAPT | |
| SCHEMBL10086319 | 0.81 | CTSK (0.42) | ITGB3ITGA2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590956-B1 | 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (S1P) receptors | MERCK SERONO SA (CH) | 2016-05-04 | — | — | EP | disclosed |
| US-9029405-B2 | 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate(SIP)receptors | MERCK SERONO S.A. (CH) | 2015-05-12 | — | — | US | disclosed |
| EP-2590956-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTORS | Merck Serono S.A. (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20130116289-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE(SIP)RECEPTORS | MERCK SERONO S.A. (CH) | 2013-05-09 | — | — | US | disclosed |
| WO-2012004287-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTORS | MERCK SERONO S.A. (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116289-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE(SIP)RECEPTORS | S1PR1, S1PR5, S1PR2 | PTPRC 1120/4885L3MBTL1 4199/4885HDAC1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.